Skip to main content

Advertisement

Table 2 Clinicopathologic features of seven patients with neuroendocrine carcinoma of the breast

From: Neuroendocrine carcinoma of the breast: a review of 126 cases in China

No. Age (years) Sex Symptom Histology TNM stage Intrinsic subtype Treatment Follow-up outcome
1 49 F Breast lump Well-differentiated T2N0M0, IIA ER3+PR2+HER2− Surgery, chemotherapy, and endocrine therapy Alive without tumor
2 78 F Breast lump Well-differentiated T1N0M0, IA ER3+PR3+HER2− Surgery, chemotherapy, and endocrine therapy Died of other causes
3 49 F Breast lump Poorly-differentiated T2N0M0, IIA ER3+PR+HER2− Surgery, chemotherapy, and endocrine therapy Alive without tumor
4 58 F Breast lump Well-differentiated T2N1M0, IIB ER2+PR2+HER2− Surgery, chemotherapy, and endocrine therapy Alive without tumor
5 43 F Breast lump and skin ulceration Well-differentiated T3N2M0, IIIA ER−PR−HER2− Surgery and chemotherapy Alive without tumor
6 60 M Breast lump Poorly-differentiated T4N0M1, IV ER−PR−HER2− Chemotherapy Lost to follow-up
7 33 F Breast lump Well-differentiated T2N1M0, IIB ER3+PR2+HER2− Surgery, chemotherapy, and endocrine therapy Alive without tumor
  1. These patients were diagnosed and treated at the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China
  2. F female, M male, ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2